1. Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India 
Dr Anna Vassall, PhD, Michael Pickles, PhD, Sudhashree Chandrashekar, MBBS, Marie-Claude Boily, PhD, Govindraj Shetty, BCom, Lorna Guinness, PhD, Catherine M Lowndes, PhD, Janet Bradley, MA, Prof Stephen Moses, MD, Prof Michel Alary, MD, Prof Peter Vickerman, DPhil 
The Lancet Global Health 
Volume 2, Issue 9, Pages e531-e540 (September 2014)
DOI: /S X(14)
Copyright © 2014 Vassall et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

2. Figure
Probability that incremental programme cost per disability-adjusted life-year (DALY) averted is below willingness-to-pay (WTP) threshold for all 22 districts (unadjusted for antiretroviral treatment [ART] costs)
(A) Assumes no correlation of mean ICERs across districts. (B) Assumes perfect correlation of mean ICERs across districts.
The Lancet Global Health 2014 2, e531-e540DOI: ( /S X(14) )
Copyright © 2014 Vassall et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions